Newsletters

NEUROFIT is a pre-clinical CRO offering set of in vitro and in vivo screening assays for psychiatry, neurology, multiple sclerosis and pain.
NEUROFIT's repertoire of screening tests is extensive and a full catalogue can be found on THERAPEUTIC AREA or TESTS with reference data.


About us

Please find our recent newsletters:

Neurofit has developed models for several neurological diseases including Alzheimer's disease, Parkinson's disease, epilepsy, neuropathic pain and peripheral neuropathies.

02 - Amyotropic Lateral Sclerosis (ALS or Lou Gehrig's disease)
03 - A functional model of motor unit : Rat nerve - Human muscle coculture
08 - In vitro assay of neurotrophic activity
13 - Model of β-Amyloid-induced neurotoxicity in rat Hippocampal neurons
14 - Wire-hanging test model
15 - Model of MPP+ - induced neurotoxicity in rat dopaminergic neurons
16 - Parkinson's Disease model
18 - Collection of brain microstructures
23 - Degeneration of intra-epidermal nerve fibers (IENF)
27 - Preclinical use of electrodiagnostic testing
28 - Sciatic Nerve Crush in mice
29 - Formalin test : Assay for anti-nociceptive drugs screening
34 - A functional model of motor unit Rat nerve - Human muscle coculture
36 - Animal model of nerve / axonal regeneration
39 - Neurite outgrowth evaluation on primary neuronal culture
40 - Parkinson disease model: 6-OHDA-mediated neuronal death
41 - Neuronal Schwann cell assays
45 - Automated formalin test - Animal model of Neuropathic pain
48 - A functional model of motor unit Rat nerve - Human muscle coculture
50 - Diabetic neuropathy
51 - Glutamate excitotoxicity
54 - Human iPSC-derived Neurons
58 - Evaluation of nerve / axonal regeneration
61 - Neurocellular model of Parkinson's disease - MPP+ neurotoxicity
69 - Chemotherapy-induced peripheral neuropathy
71 - Sciatic nerve crush, animal model of peripheral nerve injury
74 - Pharmacological relevance of the Open-Field Test
75 - Riluzole, a medication for ALS
77 - Parkinson's Disease: catalepsy model
81 - Neurodegenerative diseases: chronic glutamate excitoxicity
82 - Clinically Relevant In-vivo assay for anti-spasticity treatment

Neurofit offers a variety of established behavioural tests to assess potential anxiolytic, antidepressant or antipsychotic effects.

05 - Animal models of anxiety
06 - Conditioned Place Preference Test
17 - Rodent Elevated Plus Maze (EPM)
20 - New in-vivo model of Panic Anxiety available at Neurofit
26 - Schizophrenia
33 - Light-Dark test in the mouse: Reliable anxiety screening test
49 - Neuritogenesis, a neuroadaptive mechanism of antidepressant drugs action
52 - In-vivo screening of antidepressant: forced swimming test
53 - A clinically translatable rat model of Panic Anxiety
63 - Translational model of Schizophrenia - Phencyclidine (PCP)
66 - Evaluation of anti-depressant and/or anxiolytic drugs: Venlafaxine validation
74 - Pharmacological relevance of the Open-Field Test
76 - Elevated Plus Maze (EPM)
78 - Ketamine-sensitive assay for neuropsychiatric disorders
79 - Yohimbine-induced panic-like behavior in the rat
83 - Mouse model of schizophrenia featuring cognitive impairment
Reversal effect of Vortioxetine

Neurofit offers a range of well validated behavioural tests to assess effects on cognitive function. Our models can evaluate enhancement or disruption of processes such as attention, learning and memory.

09 - T-maze Continuous Alternation Task (T-CAT) in the mouse
11 - Novel object recognition test in the rat
12 - Reversal of MK-801-induced cognitive dysfunction by nicotine and donepezil in the T-maze assay
21 - Rapid, sensitive, cost effective assay for the screening of cognitive enhancer compounds
25 - DONEPEZIL: Neurotrophic and cognitive-enhancing drug
32 - Non-transgenic animal model of Alzheimer's disease that responds to donepezil treatment
43 - Animal model responding to ADHD therapy
46 - Reversal of MK-801-induced cognitive dysfunction by nicotine and donepezil in the T-maze assay
47 - Preclinical models for the evaluation of cognitive-enhancing drugs
55 - Animal model of inflammation-induced cognitive decline
56 - In-vivo model of cognitive disorders in schizophrenia
57 - New functional assay for Amyloid β lowering drugs
65 - Alzheimer preclinical model for the evaluation of cognitive-enhancing drugs: Memantine validation
68 - Intranasal drug administration in a classical translational model of cognitive deficits
73 - Modafinil: a "smart drug" that promotes Cognitive Function
80 - Passive Avoidance test


Neurofit provides in vivo models for inflammatory, contact allergic and autoimmune diseases.

01 - Multiple sclerosis - Drug screening
10 - Collagen-induced arthritis ( CIA ) in the rat
19 - Animal model of Relapsing-Remitting Multiple Sclerosis
22 - Robust disease model for Relapsing-Remitting Multiple Sclerosis
24 - Carrageenan: Air-Pouch model in the mouse
30 - Animal model of contact dermatitis
31 - Animal model for Rheumatoid Arthritis: Pristane induced arthritis in rat
35 - Animal Model of Allergic contact dermatitis
37 - Oxazolone-induced contact dermatitis
38 - Animal model of Relapsing-Remitting Multiple Sclerosis
42 - Cellular model of brain inflammation and neuronal death
59 - Translational model of Multiple Sclerosis - Remittance and disease relapse
60 - Translational model of DELAYED-TYPE HYPERSENSITIVITY
67 - Preclinical model of Allergic contact dermatitis: Calcipotriol (topic) and Apremilast (per os)
70 - RESVERATROL: A potent antioxidant and neuroprotector

Legende :
Animal models
Cellular models
Animal and Cellular models

If you need further information, please do not hesitate to contact us.
On a regular basis we distribute newsletters with scientific information on our research services.
If you wish to receive these, please sign up on our mailing list: